Burkitt Lymphoma Epidemiology Forecast

Key Highlights

 

• According to Orphanet (2021), in Europe and North America BL represents around half of all malignant NHL in children and around 2% in adults. In Europe, the standardized incidence ratio is 1/530,000 for individuals aged between 0 and 14 years and 1/670,000 for individuals aged between 15 and 19 years, and males are affected more than the females.

 

• According to Graham and Lynch (2021), in children younger than 18 years of age, the incidence is approximately 3-6 cases per 100,000 children annually. The same study also found that Sporadic BL has an annual estimated incidence of 4 per 1 million children less than 16 years of age whereas the incidence is around 2.5 per 1 million in adults. While immunodeficiency-associated variant has an incidence of 22 per 100,000 in the US.

 

• Burkitt Lymphoma epidemiology is segmented as Total Incident Population of Burkitt Lymphoma, Total Diagnosed Cases of Burkitt Lymphoma, Gender-specific Cases of Burkitt Lymphoma, Age-specific Cases of Burkitt Lymphoma, and Total Treated Cases of Burkitt Lymphoma] in the Burkitt Lymphoma epidemiology report.

 

Request for unlocking CAGR of Burkitt Lymphoma Epidemiology

 

DelveInsight's ‘Burkitt Lymphoma Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Burkitt Lymphoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

Burkitt Lymphoma Epidemiology Disease Understanding

The DelveInsight’s Burkitt Lymphoma market report gives a thorough understanding of Burkitt Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Burkitt Lymphoma (BL) is a form of Non-Hodgkin’s lymphoma in which cancer starts in the immune cells called B-cells. It is characterized as an aggressive non-Hodgkin B-cell Lymphoma. Non-Hodgkin’s lymphoma (NHL) is a type of cancer that begins in the lymphatic system, which is a part of body’s germ-fighting immune system. In NHL, white blood cells (WBCs) called lymphocytes grow abnormally and can form growths (tumors) throughout the body. Burkitt Lymphoma often found to be associated with Epstein Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations that cause the overexpression of oncogene c-myc.

 

The exact cause of BL is still unknown and the risk factors usually varies as per the geographic locations. Research suggests that BL is the most common in childhood cancers in reigons where there is a high incidence of malaria, like Africa. Elsewhere, the greatest risk factor is HIV.

 

Symptoms of BL depends on the type for example: Endemic variant usually starts as tumors of jaw or other facial bones and can also affect GI tract, ovaries, bones, and breast. Soradic and immunodeficiency-associated usually starts in bowel and form a bulky tumor mass in the abdomen, often with massive involvement of liver, spleen, and bone marrow. Other symptoms may include loss of appetite, weight loss, fatigue, night sweats, and unexplained fever.

 

Burkitt Lymphoma Diagnosis

The diagnosis of BL stats with a medical history and physical examination. Also, a biopsy of tumors confirms the diagnosis which is usually done by taking a sample of tissue which is then examined under a microscope. The bone marrow and central nervous system are often involved. Bone marrow and spinal fluid are usually examined to see how far the cancer has spread. Additional diagnostic tests may include: Computed tomographic (CT) imaging of the chest, abdomen, and pelvis, Chest X-ray, PET or gallium scan, bone marrow biopsy, exam of spinal fluid, blood tests to measure kidney and liver function, testing for HIV disease.

 

There are basically three types of burkitt lymphoma as per classification by the World Health Organization (WHO) i.e., Endemic (African): Primary affects African Children, Sporadic (non-African): It occurs all over the globe, Immunodeficiency-associated: It is most common in people with HIV/AIDS and can also occur in people with congenital conditions that cause immune deficiency and in organ transplant patients who take immunosuppressive drugs.

 

Burkitt Lymphoma Epidemiology

The Burkitt Lymphoma epidemiology section provides insights about historical and current Burkitt Lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Orphanet (2021), in Europe and North America BL represents around half of all malignant NHL in children and around 2% in adults. In Europe, the standardized incidence ratio is 1/530,000 for individuals aged between 0 and 14 years and 1/670,000 for individuals aged between 15 and 19 years, and males are affected more than the females.

 

• According to Graham and Lynch (2021), in children younger than 18 years of age, the incidence is approximately 3-6 cases per 100,000 children annually. The same study also found that Sporadic BL has an annual estimated incidence of 4 per 1 million children less than 16 years of age whereas the incidence is around 2.5 per 1 million in adults. While immunodeficiency-associated variant has an incidence of 22 per 100,000 in the US.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Burkitt Lymphoma epidemiology [segmented as Total Incident Population of Burkitt Lymphoma, Total Diagnosed Cases of Burkitt Lymphoma, Gender-specific Cases of Burkitt Lymphoma, Age-specific Cases of Burkitt Lymphoma, and Total Treated Cases of Burkitt Lymphoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- Burkitt Lymphoma Epidemiology

This section provides glimpse of the Burkitt Lymphoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current Burkitt Lymphoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Burkitt Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend

 

Learn how the therapeutic market will evolve and grow in the coming years: Burkitt Lymphoma Market
 

Scope of the Burkitt Lymphoma Epidemiology Report

• The report covers the descriptive overview of Burkitt Lymphoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Burkitt Lymphoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Population of Burkitt Lymphoma, Total Diagnosed Cases of Burkitt Lymphoma, Gender-specific Cases of Burkitt Lymphoma, Age-specific Cases of Burkitt Lymphoma, and Total Treated Cases of Burkitt Lymphoma

 

Burkitt Lymphoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Burkitt Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Burkitt Lymphoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Burkitt Lymphoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Burkitt Lymphoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Burkitt Lymphoma Epidemiology Segmentation

 

Burkitt Lymphoma Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Burkitt Lymphoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Burkitt Lymphoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Burkitt Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Burkitt Lymphoma?
• Out of all 7MM countries, which country would have the highest incident population of Burkitt Lymphoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Burkitt Lymphoma Disease market
• To understand the future market competition in the Burkitt Lymphoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Burkitt Lymphoma Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Burkitt Lymphoma Disease market
• To understand the future market competition in the Burkitt Lymphoma Disease market